The public meeting will be held on Wednesday August 27, 2025 and Thursday August 28, 2025, from 10 a.m. to 1 p.m. The meeting agenda, biographies, additional materials, and any other updates will also be posted to this website as they become available.
Similar Posts
OMUFA Performance Reports
Over-the-Counter Monograph Drug User Fee annual performance reports to CongressGeneric Drug Facilities, Sites and Organization Lists
Generic Drug Facilities, Sites and Organization ListsOlympus Issues Voluntary Labeling Update for Bronchoscopes Used with Laser Therapy Equipment
CENTER VALLEY, Pa., (October 31, 2025) – Olympus Corporation has announced a voluntary, global medical device corrective action to provide further clarification on the safe and effective use of bronchoscopes with laser therapy, argon plasma coagulation or high-frequency cauterization equipment durinFDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication
On August 22, 2025,the US FDA’s Center for Biologics Evaluation and Research has suspended the biologics license for Valneva Austria GmbH’s Ixchiq (Chikungunya Vaccine, Live). This vaccine was initially approved by FDA under the accelerated approval pathway in November of 2023 for the prevention ofMedisourceRx – 717970 – 12/12/2025
Compounding Pharmacy/Adulterated Drug ProductsMedWatch: The FDA Safety Information and Adverse Event Reporting Program
MedWatch is made up of voluntary and mandatory reporting on prescription medicines, over-the-counter medicines, non-vaccine biologicals, medical devices, special nutritional products, cosmetics and non-prescription human drug products marketed without an approved application.